Autopsy report · NCT01705392

Bevacizumab vs Dacarbazine in Metastatic Melanoma

“Lack of financing of the study drug. Not sufficient financial support.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 4 years 1 month before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Haukeland University Hospital

Sponsor type

University, hospital or other

Conditions

Metastatic Malignant Melanoma; Unresectable Malignant Melanoma

Interventions

Bevacizumab; Propranolol; Enalapril; Dacarbazine

Participants

2

Sites

1

Countries

Norway

Trials that died the same way

• Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures
  “Lack of funding to support the study” (76% match in meaning)
• Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
  “due to business decision regarding the study drug.” (75% match in meaning)
• Exenatide For Reducing the Reinforcing Effects of Cocaine
  “The study was closed due to the inability to acquire the study drug.” (74% match in meaning)
• Study of EQU-001 for Uncontrolled Focal Onset Seizures
  “insufficient funding to complete the study” (74% match in meaning)
• Midodrine Use in Septic Shock
  “No funding for the study; not enough staff” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.